Scientific Papers

Glucose fluctuations aggravate myocardial fibrosis via activating the CaMKII/Stat3 signaling in type 2 diabtetes | Diabetology & Metabolic Syndrome


  • Battelino T, Alexander CM, Amiel SA, Arreaza-Rubin G, Beck RW, Bergenstal RM, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023;11(1):42–57.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ceriello A, Prattichizzo F, Phillip M, Hirsch IB, Mathieu C, Battelino T. Glycaemic management in Diabetes: old and new approaches. Lancet Diabetes Endocrinol. 2022;10(1):75–84.

    Article 
    PubMed 

    Google Scholar
     

  • Wang Y, Zhou J, Qi W, Zhang N, Tse G, Li G, et al. Visit-to-visit variability in fasting blood glucose predicts the new-onset Heart Failure: results from two large Chinese cohorts. Curr Probl Cardiol. 2023;48(9):101842.

    Article 
    PubMed 

    Google Scholar
     

  • Zhang J, Yang J, Liu L, Li L, Cui J, Wu S, et al. Significant abnormal glycemic variability increased the risk for arrhythmias in elderly type 2 diabetic patients. BMC Endocr Disord. 2021;21(1):83.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li F, Zhang L, Shen Y, Liu HH, Zhang ZY, Hu G, et al. Higher glucose fluctuation is associated with a higher risk of Cardiovascular Disease: insights from pooled results among patients with Diabetes. J Diabetes. 2023;15(5):368–81.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang ZY, Dang SP, Li SS, Liu Y, Qi MM, Wang N, et al. Glucose fluctuations aggravate myocardial fibrosis via the nuclear factor-κB-mediated nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome activation. Front Cardiovasc Med. 2022;9:748183.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Benchoula K, Mediani A, Hwa WE. The functions of ca(2+)/calmodulin-dependent protein kinase II (CaMKII) in Diabetes progression. J Cell Commun Signal. 2023;17(1):25–34.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lebek S, Chemello F, Caravia XM, Tan W, Li H, Chen K, et al. Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac Disease. Science. 2023;379(6628):179–85.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Reyes Gaido OE, Nkashama LJ, Schole KL, Wang Q, Umapathi P, Mesubi OO, et al. CaMKII as a therapeutic target in Cardiovascular Disease. Annu Rev Pharmacol Toxicol. 2023;63:249–72.

    Article 
    PubMed 

    Google Scholar
     

  • Hegyi B, Bers DM, Bossuyt J. CaMKII signaling in Heart Diseases: emerging role in diabetic cardiomyopathy. J Mol Cell Cardiol. 2019;127:246–59.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lu S, Liao Z, Lu X, Katschinski DM, Mercola M, Chen J, et al. Hyperglycemia acutely increases cytosolic reactive oxygen species via o-linked GlcNAcylation and CaMKII activation in mouse ventricular myocytes. Circ Res. 2020;126(10):e80–e96.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen Y, Li X, Hua Y, Ding Y, Meng G, Zhang W. RIPK3-mediated necroptosis in diabetic cardiomyopathy requires CaMKII activation. Oxid Med Cell Longev 2021; 2021:6617816.

  • Das K, Basak M, Mahata T, Kumar M, Kumar D, Biswas S, et al. RGS11-CaMKII complex mediated redox control attenuates chemotherapy-induced cardiac fibrosis. Redox Biol. 2022;57:102487.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wu X, Xu M, Geng M, Chen S, Little PJ, Xu S, et al. Targeting protein modifications in metabolic Diseases: molecular mechanisms and targeted therapies. Signal Transduct Target Ther. 2023;8(1):220.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen Z, Zhou H, Huang X, Wang S, Ouyang X, Wang Y, et al. Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway. Bioengineered. 2022;13(5):12772–82.

  • Huo S, Shi W, Ma H, Yan D, Luo P, Guo J et al. Alleviation of inflammation and oxidative stress in pressure overload-induced cardiac remodeling and heart failure via IL-6/STAT3 inhibition by raloxifene. Oxid Med Cell Longev 2021; 2021:6699054.

  • Zhuang L, Jia K, Chen C, Li Z, Zhao J, Hu J, et al. DYRK1B-STAT3 drives cardiac hypertrophy and Heart Failure by impairing mitochondrial bioenergetics. Circulation. 2022;145(11):829–46.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chen Q, Lv J, Yang W, Xu B, Wang Z, Yu Z, et al. Targeted inhibition of STAT3 as a potential treatment strategy for Atherosclerosis. Theranostics. 2019;9(22):6424–42.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Luo W, Huang L, Wang J, Zhuang F, Xu Z, Yin H, et al. Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 Diabetes. J Endocrinol. 2019;242(3):199–210.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Unudurthi SD, Nassal D, Greer-Short A, Patel N, Howard T, Xu X, et al. βIV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload. J Clin Invest. 2018;128(12):5561–72.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ying C, Zhou X, Chang Z, Ling H, Cheng X, Li W. Blood glucose fluctuation accelerates renal injury involved to inhibit the AKT signaling pathway in diabetic rats. Endocrine. 2016;53(1):81–96.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wu W, Chai Q, Zhang Z. Glucose fluctuation accelerates cardiac injury of diabetic mice via sodium-dependent glucose cotransporter 1 (SGLT1). Arch Biochem Biophys. 2021;709:108968.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wang P, Xu S, Xu J, Xin Y, Lu Y, Zhang H, et al. Elevated MCU expression by CaMKIIδB limits pathological cardiac remodeling. Circulation. 2022;145(14):1067–83.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang L, Li F, Liu HH, Zhang ZY, Yang F, Qian LL, et al. Glycaemic variability and risk of adverse cardiovascular events in acute coronary syndrome. Diab Vasc Dis Res. 2022;19(6):14791641221137736.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ji M, Su L, Liu L, Zhuang M, Xiao J, Guan Y, et al. CaMKII regulates the proteins TPM1 and MYOM2 and promotes diacetylmorphine-induced abnormal cardiac rhythms. Sci Rep. 2023;13(1):5827.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lebek S, Pichler K, Reuthner K, Trum M, Tafelmeier M, Mustroph J, et al. Enhanced CaMKII-dependent late I(na) induces atrial proarrhythmic activity in patients with sleep-disordered breathing. Circ Res. 2020;126(5):603–15.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wei X, Jin J, Wu J, He Y, Guo J, Yang Z, et al. Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway. Cardiovasc Res. 2023;119(9):1842–55.

  • Zhang J, Liang R, Wang K, Zhang W, Zhang M, Jin L, et al. Novel CaMKII-δ inhibitor hesperadin exerts dual functions to ameliorate cardiac ischemia/reperfusion injury and inhibit Tumor growth. Circulation. 2022;145(15):1154–68.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Li Y, Liu X, Wan L, Han B, Ma S, Pan H, et al. Metformin suppresses cardiac fibroblast proliferation under high-glucose conditions via regulating the mitochondrial complex I protein Grim-19 involved in the Sirt1/Stat3 signaling pathway. Free Radic Biol Med. 2023;206:1–12.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Qing Z, Yuan W, Wang J, Song W, Luo J, Wu X, et al. Verapamil inhibited the development of ureteral stricture by blocking CaMKII-mediated STAT3 and Smad3/JunD pathways. Int Urol Nephrol. 2022;54(11):2855–66.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ni Y, Deng J, Bai H, Liu C, Liu X, Wang X. CaMKII inhibitor KN-93 impaired angiogenesis and aggravated cardiac remodelling and Heart Failure via inhibiting NOX2/mtROS/p-VEGFR2 and STAT3 pathways. J Cell Mol Med. 2022;26(2):312–25.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Altara R, Harmancey R, Didion SP, Booz GW, Zouein FA. Cardiac STAT3 deficiency impairs contractility and metabolic homeostasis in Hypertension. Front Pharmacol. 2016;7:436.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     



  • Source link